Real-world HIV RNA and Antigen/Antibody Testing Among People Who Use Long-acting Injectable Preexposure Prophylaxis
The frequency of breakthrough HIV infection or LEVI syndrome in this real-world cohort was low during initial 3-7 months of injectable PrEP use. Ongoing assessment of the added value of HIV RNA testing for monitoring during CAB-LA PrEP use is warranted.
Authors
- Weiming Zhu (ORCID: https://orcid.org/0000-0002-9042-6202)
- Kevin P. Delaney (ORCID: https://orcid.org/0000-0002-7562-7647)
- Karen W. Hoover (ORCID: https://orcid.org/0000-0003-4942-7905)
- Rupa Patel (ORCID: https://orcid.org/0000-0002-0329-7036)
- Athena P. Kourtis (ORCID: https://orcid.org/0000-0003-1585-1310)
- Ya-Lin A. Huang (ORCID: https://orcid.org/0000-0003-3137-8594)
Institutions
- Centers for Disease Control and Prevention (US)
- Centers for Disease Control and Prevention (UG)
- The Centers (US)
- Centers for Disease Control and Prevention (KE)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1093/cid/ciaf173
- Citations
- 4
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 5.58